Treatment of silicosis with hepatocyte growth factor-modified autologous bone marrow stromal cells: a non-randomized study with follow-up.

摘要: Pulmonary silicosis is an irreversible and untreatable disease that characterized by interstitial lesions perpetual fibrosis in the lungs. This study was performed to determine whether mesenchymal stem cells (MSCs) hepatocyte growth factor (HGF) could exhibit therapeutic effects on human silicosis. non-randomized uncontrolled trial comprised four patients with pulmonary who had developed lung received autologous bone marrow MSCs previously transfected a vector containing HGF cDNA (MSCs/HGF). MSCs/HGF were intravenously administered weekly for three consecutive weeks at dose of 2 x 10(6) cells/kg. function, high kilo-voltage chest X-ray radiography, computed tomography (CT) scan, peripheral blood lymphocyte subset serum IgG concentrations evaluated after cell therapy. The treatment found be generally safe. Symptoms such as cough distress gradually ameliorated six months post-therapy, accompanied significant improvement function. ratios CD4- CD8- positive increased (P < 0.05). Furthermore, levels these decreased reached normal range CT scans showed partial absorption nodular reticulonodular lungs during follow-up least 12 months. effectiveness this novel regimen observed suggests placebo-controlled clinical needs developed. carries registration No. NCT01977131 (ClinicalTrials.gov).